BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32317288)

  • 21. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
    Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
    Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.
    Markowitz P; Patel M; Groisberg R; Aisner J; Jabbour SK; De S; Ganesan S; Malhotra J
    Cancer Treat Res Commun; 2020; 25():100232. PubMed ID: 33166854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
    Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
    Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.
    Zhang Y; Chen Y; Yang C; Seger N; Hesla AC; Tsagkozis P; Larsson O; Lin Y; Haglund F
    Mod Pathol; 2021 Nov; 34(11):2020-2027. PubMed ID: 34108637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
    Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
    Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
    Campanella NC; Silva EC; Dix G; de Lima Vazquez F; Escremim de Paula F; Berardinelli GN; Balancin M; Chammas R; Mendoza Lopez RV; Silveira HCS; Capelozzi VL; Reis RM
    Pathobiology; 2020; 87(3):208-216. PubMed ID: 32369821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
    Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
    Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.